A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Fresenius Kabi Awarded Technology Breakthrough Agreement with Premier, Inc. for the Ivenix Infusion System

Fresenius Kabi announced today it has been awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. Effective May 1, 2023, the new agreement allows Premier members, at their discretion, to benefit from special pricing and terms pre-negotiated by Premier for the Ivenix Infusion System from Fresenius Kabi.

“We deeply appreciate this vote of confidence in the Ivenix Infusion System and look forward to working with Premier members,” said Christian Hauer, executive board member and president, Fresenius Kabi MedTech. “Health systems and their nursing teams face many day-to-day challenges associated with infusion therapy. The Ivenix Infusion System is designed to improve the simplicity, intelligence and reliability of infusion pumps. We’re pleased Premier chose to make our smart infusion system available to its members.”

The Ivenix Infusion System is designed to overcome deficiencies in legacy pumps. The Ivenix patented pumping technology delivers critical medications with flow that is measured and controlled to help optimize safety. The pump operates unaffected by external conditions such as bag height, back pressure, and fluid viscosity to deliver accurate medication delivery, and it protects patients from uncontrolled flow.

The Ivenix Large-Volume Pump includes a large, smartphone-like touchscreen that allows clinicians to auto-program, review, and accept medication orders on the pump. The built-in integration engine within the Ivenix Infusion System supports secure interoperability with leading electronic medical records (EMR) systems. The Ivenix system from Fresenius Kabi also offers valuable tools to automate testing, reducing the implementation timeline and the resources needed to synchronize the drug library with the EMR formulary.

The Ivenix platform also facilitates enterprise-wide, centralized management of the entire pump fleet. This device command center allows for comprehensive oversight of the infusion pump fleet from device utilization to location awareness, proactive maintenance, user management, and remote software and security updates—without wasting valuable time hunting and gathering devices.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy